Quick Answer
CytoDyn Inc. reported Stockholders Equity of -$96.04 million for fiscal year 2025.
CytoDyn Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$96.04M | +17.7% |
| 2024 | -$116.76M | -6.6% |
| 2023 | -$109.50M | -16.0% |
| 2022 | -$94.40M | -349.1% |
| 2021 | -$21.02M | -747.2% |
| 2020 | -$2.48M | +72.2% |
| 2019 | -$8.91M | +32.3% |
| 2018 | -$13.16M | -1092.7% |
| 2017 | -$1.10M | -110.8% |
| 2016 | $10.21M | +195.4% |
| 2015 | -$10.69M | -372.6% |
| 2014 | $3.92M | +1851.7% |
| 2013 | -$223.9K | +94.4% |
| 2012 | -$3.97M | +20.7% |
| 2011 | -$5.01M | -55.7% |
| 2010 | -$3.22M | -43.0% |
| 2009 | -$2.25M | -36.6% |
| 2008 | -$1.65M | -53.2% |
| 2007 | -$1.07M | -65.0% |
| 2006 | -$651.0K | +14.3% |
| 2005 | -$759.8K | -633035.8% |
| 2004 | -$120.00 | +99.9% |
| 2003 | -$145.2K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | -$119.75M | -34.0% | -20.3% |
| August 31, 2025 | -$99.50M | -16.8% | -3.6% |
| May 31, 2025 | -$96.04M | +17.7% | -3.3% |
| February 28, 2025 | -$92.98M | +22.1% | -4.0% |
| November 30, 2024 | -$89.39M | +21.8% | -4.9% |
| August 31, 2024 | -$85.21M | +27.1% | +27.0% |
| May 31, 2024 | -$116.76M | -6.6% | +2.2% |
| February 29, 2024 | -$119.38M | -11.6% | -4.4% |
- CytoDyn Inc. showed an increase of +17.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2003–2025 period, CytoDyn Inc.’s stockholders equity has declined by 66041.9% (from -$145.2 thousand to -$96.04 million).
- The most recent figure is from CytoDyn Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: